This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Yuhan Corporation. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2025
Title: Dae-Gyu Park: Innovator in Aminopyrimidine Derivatives
Introduction
Dae-Gyu Park is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aminopyrimidine derivatives. With a total of 4 patents to his name, Park's work has the potential to impact the treatment of various diseases.
Latest Patents
One of his latest patents is focused on an improved process for preparing aminopyrimidine derivatives or pharmaceutically acceptable salts. This invention specifically targets selective inhibitory activity against protein kinases, especially those associated with mutant epidermal growth factor receptors. Additionally, the patent provides novel intermediates that are useful for this process and outlines methods for preparing these intermediates.
Career Highlights
Dae-Gyu Park is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to further his research and development efforts in the pharmaceutical sector.
Collaborations
Some of his notable coworkers include Sang-Ho Oh and Ja-Heouk Khoo, who have collaborated with him on various projects within the company.
Conclusion
Dae-Gyu Park's innovative work in the field of aminopyrimidine derivatives showcases his commitment to advancing pharmaceutical science. His contributions are poised to make a significant impact on the treatment of diseases related to protein kinases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile